Google has an internal team that reviews AI applications in sensitive areas — like health and safety — against its AI Principles before deployment.
This provision means there is supposedly a team at Google reviewing whether AI tools in sensitive areas like health are safe before they reach you — but there is no public reporting on how many applications were reviewed, rejected, or modified as a result.
Cross-platform context
See how other platforms handle Internal AI Review Process for Sensitive Applications and similar clauses.
Compare across platforms →The existence of a formal internal review process is notable, but the process is entirely internal with no public reporting on outcomes, creating an accountability gap that regulators and consumers cannot independently verify.
REGULATORY FRAMEWORK: This internal review process engages the EU AI Act Arts. 9 and 17 (risk management systems and quality management systems for high-risk AI providers); the NIST AI Risk Management Framework Govern function; FDA guidance on Software as a Medical Device (SaMD) pre-market review; and emerging corporate AI governance standards (ISO/IEC 42001:2023 AI Management System). No regulatory authority directly mandates this specific form of internal review, but the EU AI Act will require documented conformity assessments that this review process may partially satisfy.
Compliance intelligence locked
Regulatory citations, enforcement risk, and due diligence action items.
Watcher: regulatory citations. Professional: full compliance memo.